Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Checkpoint Therapeutics Inc. currently manages 1 pending office action. The portfolio's active prosecution involves 1 distinct examiner, though the data reports 0 distinct art units for the current pending matters. This indicates a specific point of interaction within the patent office where the role of the individual examiner is the primary observable metric. The presence of 0 distinct art units suggests a highly specialized focus for the pending application.
OUSPENSKI, ILIA I is the busiest examiner, currently handling 1 pending office action. This 1 pending matter accounts for the entire pending workload of the company. With 1 distinct examiner involved, the prosecution profile is concentrated, making the specific habits and requirements of OUSPENSKI, ILIA I the central focus for the company's legal representatives. Success in this matter depends on navigating the specific review criteria of this individual examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18377702 | PD-L1-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME | OUSPENSKI, ILIA I | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18377702 | PD-L1-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME | OUSPENSKI, ILIA I | — | DP | Non-Final OA | — | Pending | Oct 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial